Literature DB >> 22704963

Intratumoral heterogeneity of microRNA expression in breast cancer.

Mithu Raychaudhuri1, Tibor Schuster, Theresa Buchner, Katharina Malinowsky, Holger Bronger, Ulrike Schwarz-Boeger, Heinz Höfler, Stefanie Avril.   

Abstract

Profiling studies have identified specific microRNA (miRNA) signatures in malignant tumors including breast cancer. Our aim was to assess intratumoral heterogeneity in miRNA expression levels within primary breast cancers and between axillary lymph node metastases from the same patient. Specimens of 16 primary breast cancers were sampled in 8-10 distinct locations including the peripheral, intermediate, and central tumor zones, as well as two to five axillary lymph node metastases (n = 9). Total RNA was extracted from 132 paraffin-embedded samples, and the expression of miR-10b, miR-210, miR-31, and miR-335 was assessed as well as the reproducibility of RNA extraction and miRNA analysis by quantitative RT-PCR. Considerable intratumoral heterogeneity existed for all four miRNAs within primary breast cancers (CV 40%). No significant differences within (CV 34%) or between different tumor zones (CV 33%) were found. A similar variation in miRNA expression was observed between corresponding lymph node metastases (mean CV 40%). In comparison, the variation among different patients showed a CV of 80% for primary tumors and 103% for lymph node metastases. Both miRNA extraction procedures and quantitative RT-PCR showed high reproducibility (CV ≤ 2%). Thus, the intratumoral heterogeneity of miRNA expression in breast cancers can lead to significant sampling bias. Assessment of breast cancer miRNA profiles may require sampling at several different tumor locations and of several tumor-involved lymph nodes when deriving miRNA expression profiles of metastases.
Copyright © 2012 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22704963     DOI: 10.1016/j.jmoldx.2012.01.016

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  20 in total

Review 1.  Micro-RNAs in inflammatory diseases and as a link between inflammation and cancer.

Authors:  R Ranjha; J Paul
Journal:  Inflamm Res       Date:  2013-02-17       Impact factor: 4.575

Review 2.  Pathology to enhance precision medicine in oncology: lessons from landscape ecology.

Authors:  Mark C Lloyd; Katarzyna A Rejniak; Joel S Brown; Robert A Gatenby; Emily S Minor; Marilyn M Bui
Journal:  Adv Anat Pathol       Date:  2015-07       Impact factor: 3.875

3.  MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.

Authors:  Mithu Raychaudhuri; Holger Bronger; Theresa Buchner; Marion Kiechle; Wilko Weichert; Stefanie Avril
Journal:  Breast Cancer Res Treat       Date:  2017-02-08       Impact factor: 4.872

Review 4.  Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.

Authors:  S Avril
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

Review 5.  [microRNA expression in breast development and breast cancer].

Authors:  S Avril
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

6.  Expression of platelet-derived growth factor BB, erythropoietin and erythropoietin receptor in canine and feline osteosarcoma.

Authors:  F R L Meyer; R Steinborn; H Grausgruber; B Wolfesberger; I Walter
Journal:  Vet J       Date:  2015-06-06       Impact factor: 2.688

7.  Genetic and epigenetic analysis of putative breast cancer stem cell models.

Authors:  Marija Balic; Daniela Schwarzenbacher; Stefanie Stanzer; Ellen Heitzer; Martina Auer; Jochen B Geigl; Richard J Cote; Ram H Datar; Nadia Dandachi
Journal:  BMC Cancer       Date:  2013-07-24       Impact factor: 4.430

8.  Developing a prognostic micro-RNA signature for human cervical carcinoma.

Authors:  Christine How; Melania Pintilie; Jeff P Bruce; Angela B Y Hui; Blaise A Clarke; Philip Wong; Shaoming Yin; Rui Yan; Daryl Waggott; Paul C Boutros; Anthony Fyles; David W Hedley; Richard P Hill; Michael Milosevic; Fei-Fei Liu
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

9.  Common protein biomarkers assessed by reverse phase protein arrays show considerable intratumoral heterogeneity in breast cancer tissues.

Authors:  Katharina Malinowsky; Mithu Raychaudhuri; Theresa Buchner; Sabrina Thulke; Claudia Wolff; Heinz Höfler; Karl-Friedrich Becker; Stefanie Avril
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

10.  Personalized medicine in screening for malignant disease: a review of methods and applications.

Authors:  F Schmalfuss; P L Kolominsky-Rabas
Journal:  Biomark Insights       Date:  2013-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.